Genetically Informed Screening for Early-Stage Type 1 Diabetes

This study is a test to find out if genetic information can be used to help healthcare providers identify diseases. Specifically, the investigators want to find out how genetic information can help healthcare providers identify people who may benefit from early screening for type 1 diabetes, even before people feel sick. This study aims to guide future research to improve screening, prevent disease, slow progression, and expand treatment options for type 1 diabetes.

Inclusion Criteria: * Adults aged 18-79 years who had participated in the Mass General Brigham (MGB) Biobank and agreed to be recontacted for future study Exclusion Criteria: * Individuals with current or prior treatment with immune checkpoint inhibitors (e.g., PD-1, PD-L1, or CTLA-4 inhibitors), as well as individuals with diabetes secondary to pancreatic disease, including pancreatic cancer, pancreatitis, pancreatic surgery/pancreatectomy, cystic fibrosis, or hemochromatosis